- Home
- SI vs GALT Comparison
SI vs GALT Comparison
Compare SI & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SI | GALT |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.2M | 397.3M |
| IPO Year | 2025 | 2008 |
Fundamental Metrics
Financial Performance| Metric | SI | GALT |
|---|---|---|
| Price | $21.82 | $3.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $27.00 | N/A |
| AVG Volume (30 Days) | 87.4K | ★ 191.8K |
| Earning Date | 11-05-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.08 | 36.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,317,000.00 | N/A |
| Revenue This Year | $46.44 | N/A |
| Revenue Next Year | $27.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 49.63 | N/A |
| 52 Week Low | $12.00 | $2.03 |
| 52 Week High | $24.60 | $7.13 |
Technical Indicators
Market Signals| Indicator | SI | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 65.07 | 47.32 |
| Support Level | $17.83 | $2.71 |
| Resistance Level | $23.08 | $4.10 |
| Average True Range (ATR) | 1.31 | 0.27 |
| MACD | 0.23 | 0.01 |
| Stochastic Oscillator | 83.01 | 59.37 |
Price Performance
Historical ComparisonAbout SI Shoulder Innovations Inc.
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System. Geographically, the company operates in United States and are planning to expand.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.